Search Results

Melior Discovery, Inc. announced that it has been selected as the CRO of the Year by Life Sciences Review magazine.

Melior Discovery, Inc. (Melior) announced today significant additions to its management organization.

Melior Pharmaceuticals (Melior) announced that it completed a definitive licensing agreement with Adhera Therapeutics, Inc . (OTCPK: ATRX; Adhera) for Melior’s Parkinson’s disease (PD) candidate, MLR-1019 (armesocarb).

Melior Pharmaceuticals (Melior) announced that it has signed a “letter of intent” with Adhera Therapeutics, Inc . (OTCPK: ATRX; Adhera) for the acquisition of Melior’s Parkinson’s disease (PD) candidate, MLR-1019 (armesocarb).

Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) is pleased to announce that it has entered into an agreement for the assignment of Adhera Therapeutics, Inc.’s (“Adhera’s”) rights to tolimidone (formerly coded MLR-1023) under an exclusive, worldwide, sub-licensable license from Melior Pharmaceuticals I, Inc. (“Melior”) to develop, manufacture, commercialize or otherwise exploit tolimidone.

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”)(Nasdaq: BDRX) today announced that the U.S. Patent and Trademark Office allowed U.S. patent application No. 16/546,595 titled “Prevention of Pancreatic Cell Degeneration” which was exclusively licensed to Biodexa by Melior Pharmaceuticals, Inc., along with other patents, in a transaction which closed in December 2023.

Melior’s therapeutic candidate, tolimidone, is: Expected to mitigate the probability and severity of COVID-19 subjects developing severe lung complications A repositioned drug that has been demonstrated to be safe and well-tolerated in previous clinical studies

Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.

Melior’s therapeutic candidate, tolimidone, is: Expected to mitigate the probability and severity of COVID-19 subjects developing severe lung complications A repositioned drug that has been demonstrated to be safe and well-tolerated in previous clinical studies

Japan-based Taiho Pharmaceutical has worked with Araris Biotech since 2023 developing antibody-drug conjugates for the oncology space.